https://www.selleckchem.com/pr....oducts/abbv-cls-484.
Median baseline DSS was 6 in both arms. By week 24, patients treated with golimumab plus MTX exhibited significantly greater improvements in DSS relative to MTX monotherapy (median change of 5 vs 2 points, respectively; p=0.026). In the golimumab plus MTX arm, significantly higher proportions of patients achieved at least 50% or 70% improvement in DSS and 20%, 50% or 70% improvement in LDI in comparison to MTX monotherapy. CONCLUSIONS The combination of golimumab and MTX as first-line bDMARD therapy is superior to MTX monotherapy f
Gefällt mir
Kommentar
Teilen
